Preparation of Multivesicular Liposomes for the Loco-regional Delivery of Vancomycin Hydrochloride Using Active Loading Method: Drug Release and Antimicrobial Properties
Overview
Authors
Affiliations
Over the last few years, among controlled-release delivery systems, multivesicular liposomes (MVLs) have attracted attention due to their unique benefits as a loco-regional drug delivery system. Considering the clinical limitations of the current treatment strategies for osteomyelitis, MVLs can be a suitable carrier for the local delivery of effective antibiotics. This study aimed to prepare vancomycin hydrochloride (VAN HL) loaded MVLs using the active loading method which to the best of our knowledge has not been previously reported. Empty MVLS were prepared by the double emulsion (w/o/w) method and VAN HL was loaded into the prepared liposomes by the ammonium gradient method. After full characterization, the release profile of VAN HL from MVLs was assessed at two different pH values (5.5 and 7.4), and compared with the release profile of the free drug and also passively loaded MVLs. antimicrobial activities were evaluated using the disc diffusion method. Our results demonstrated that the encapsulation efficiency was higher than 90% in the optimum actively loaded MVL. The free VAN HL was released within 6-8 h, while the passively loaded MVLs and the optimum actively loaded MVL formulation released the drug in 6 days and up to 19 days, respectively. The released drug showed effective antibacterial activity against osteomyelitis-causing pathogens. In conclusion, the prepared formulation offered the advantages of sustained-release properties, appropriate particle size as well as being composed of biocompatible materials, and thus could be a promising candidate for the loco-regional delivery of VAN HL and the management of osteomyelitis.
Nakmode D, Singh B, Abdella S, Song Y, Garg S Drug Deliv Transl Res. 2024; 15(4):1156-1180.
PMID: 39661312 PMC: 11870889. DOI: 10.1007/s13346-024-01747-y.
Advanced Drug Delivery Technologies for Enhancing Bioavailability and Efficacy of Risperidone.
Rathi R, Mehetre N, Goyal S, Singh I, Huanbutta K, Sangnim T Int J Nanomedicine. 2024; 19():12871-12887.
PMID: 39640049 PMC: 11618854. DOI: 10.2147/IJN.S492684.
Basu S, Biswas P, Anto M, Singh N, Mukherjee K 3 Biotech. 2024; 14(12):289.
PMID: 39507057 PMC: 11534931. DOI: 10.1007/s13205-024-04135-y.
Recent advances in nanostructured delivery systems for vancomycin.
Ansari M, Shahlaei M, Hosseinzadeh S, Moradi S Nanomedicine (Lond). 2024; 19(23):1931-1951.
PMID: 39143926 PMC: 11457640. DOI: 10.1080/17435889.2024.2377063.